• 文章类型: Journal Article
    在急性肾损伤(AKI)期间使用钠-葡萄糖协同转运蛋白2抑制剂(SGLT2is)与主要不良肾事件(MAKE)的发生率之间的关联尚不清楚。
    这项回顾性队列研究纳入了AKI患者,并比较了住院期间接受SGLT2is治疗的患者和未接受SGLT2i治疗的患者的结局。SGLT2i与MAKE在10天和30-90天使用的关联,每个单独的MAKE组件,并对预先指定的患者亚组进行分析.
    从2021年到2023年,374例患者被纳入研究-316例未使用SGLT2i,58例使用SGLT2i。接受SGLT2is治疗的患者年龄较大;糖尿病患病率更高,高血压,慢性心力衰竭,和慢性肾脏疾病;需要血液透析的频率较低;与未接受SGLT2is治疗的患者相比,出现3期AKI的频率较低。最近邻匹配的Logistic回归分析显示,SGLT2i的使用与MAKE10(OR1.08[0.45-2.56])或MAKE30-90(OR0.76[0.42-1.36])的风险无关。对于死亡,逐步方法表明SGLT2i的使用与风险降低相关(OR0.08;0.01-0.64),肾脏替代疗法(KRT)没有效果。在接受SGLT2is治疗的AKI患者中,MAKE风险降低的患者亚组是年龄超过61岁的患者,eGFR>81的患者和无高血压或DM病史的患者(均p≤0.05)。
    在AKI期间使用SGLT2is对短期或中期MAKE没有影响,但某些亚组患者可能从SGLT2i治疗中获益.
    UNASSIGNED: The association between the administration of sodium-glucose cotransporter 2 inhibitors (SGLT2is) during acute kidney injury (AKI) and the incidence of major adverse kidney events (MAKEs) is not known.
    UNASSIGNED: This retrospective cohort study included patients with AKI and compared the outcomes for those who were treated with SGLT2is during hospitalization and those without SGLT2i treatment. The associations of SGLT2i use with MAKEs at 10 and 30-90 days, each individual MAKE component, and the pre-specified patient subgroups were analyzed.
    UNASSIGNED: From 2021 to 2023, 374 patients were included in the study-316 without SGLT2i use and 58 with SGLT2i use. Patients who were treated with SGLT2is were older; had a greater prevalence of diabetes, hypertension, chronic heart failure, and chronic kidney disease; required hemodialysis less often; and presented stage 3 AKI less frequently than those who were not treated with SGLT2is. Logistic regression analysis with nearest-neighbor matching revealed that SGLT2i use was not associated with the risk of MAKE10 (OR 1.08 [0.45-2.56]) or with MAKE30-90 (OR 0.76 [0.42-1.36]). For death, the stepwise approach demonstrated that SGLT2i use was associated with a reduced risk (OR 0.08; 0.01-0.64), and no effect was found for kidney replacement therapy (KRT). The subgroups of patients who experienced a reduction in the risk of MAKEs in patients with AKI treated with SGLT2is were those older than 61 years, those with an eGFR >81, and those without a history of hypertension or DM (p ≤ 0.05 for all).
    UNASSIGNED: The use of SGLT2is during AKI had no effect on short- or medium-term MAKEs, but some subgroups of patients may have experienced benefits from SGLT2i treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    原发性透明细胞肾细胞癌(ccRCC)的肾切除术后复发的风险仅根据临床标准在日常实践中进行估计。这项研究的目的是评估常见体细胞突变与明确治疗后ccRCC患者的肿瘤侵袭性和预后的相关性。
    使用15基因靶向下一代测序(NGS)小组分析了37例接受根治性肾切除术的ccRCC患者的原发性肿瘤是否存在体细胞突变。在研究队列(n=37)中调查了与组织病理学特征和结果的关联,并在癌症基因组图谱(TCGA)ccRCC队列(n=451)中进行了验证。
    VHL是最常见的突变基因(51%),其次是PBRM1(27%),BAP1(13%),SETD2(13%),KDM5C(5%),ATM(5%),MTOR(5%),和PTEN(3%)。三分之一的患者在15个基因组中没有任何体细胞突变。绝大多数完全没有突变或VHL突变(51%)的肿瘤更常见的是较小的大小(pT1-2)和早期(I/II),而有或没有VHL的各种组合中任何其他基因突变的存在在较大(pT3)和较高分期(III)的肿瘤中富集(p=0.02).在具有未突变的肿瘤或仅VHL突变的患者中没有发现复发,而在具有非VHL体细胞突变的患者中没有发现3次复发(p=0.06)。PBRM1,BAP1,SETD2,KDM5C中存在体细胞突变,ATM,MTOR,451名TCGAccRCC患者中的PTEN基因与肿瘤未改变的患者相比,无病生存期(DFS)显着缩短(q=0.01)。
    这项正在进行的研究的初步发现支持非VHL突变的预后价值,包括PBRM1,BAP1,SETD2,KDM5C,ATM,MTOR,和PTEN在原发性ccRCC肿瘤中作为早期复发的替代和辅助免疫检查点抑制的潜在选择。
    UNASSIGNED: The risk of recurrence after nephrectomy for primary clear cell renal cell carcinoma (ccRCC) is estimated in daily practice solely based on clinical criteria. The aim of this study was to assess the prognostic relevance of common somatic mutations with respect to tumor aggressiveness and outcomes of ccRCC patients after definitive treatment.
    UNASSIGNED: Primary tumors from 37 patients with ccRCC who underwent radical nephrectomy were analyzed for presence of somatic mutations using a 15-gene targeted next-generation sequencing (NGS) panel. Associations to histopathologic characteristics and outcomes were investigated in the study cohort (n=37) and validated in The Cancer Genome Atlas (TCGA) ccRCC cohort (n=451).
    UNASSIGNED: VHL was the most frequently mutated gene (51%), followed by PBRM1 (27%), BAP1 (13%), SETD2 (13%), KDM5C (5%), ATM (5%), MTOR (5%), and PTEN (3%). One-third of patients did not have any somatic mutations within the 15-gene panel. The vast majority of tumors harboring no mutations at all or VHL-only mutations (51%) were more frequently of smaller size (pT1-2) and earlier stage (I/II), whereas presence of any other gene mutations in various combinations with or without VHL was enriched in larger (pT3) and higher stage tumors (III) (p=0.02). No recurrences were noted in patients with unmutated tumors or VHL-only mutations as opposed to three relapses in patients with non- VHL somatic mutations (p=0.06). Presence of somatic mutations in PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, or PTEN genes in 451 TCGA ccRCC patients was associated with a significantly shorter disease-free survival (DFS) compared to those with unaltered tumors (q=0.01).
    UNASSIGNED: Preliminary findings from this ongoing study support the prognostic value of non- VHL mutations including PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, and PTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    放射性核素探针靶向前列腺特异性膜抗原(PSMA)用于前列腺癌(PCa)的诊断和治疗。最近的研究表明,PSMA在肿瘤新生血管内皮细胞中表达,例如在肝脏恶性肿瘤中。我们报告了一例使用18F-PSMA-1007和18F-氟脱氧葡萄糖(FDG)正电子发射形貌(PET)/MRI.18F-PSMA-1007PET/MRI检测的偶发性肝内胆管癌(ICC)的PCa病例,我们的PCa患者有一个肝脏病变有较高的PSMA摄取。18F-FDGPET/MRI显示肝脏病变中FDG摄取最少。组织病理学检查显示肝脏病变为中度至低分化胆管癌。我们的研究,和其他人一起,证明了肝脏恶性肿瘤,比如ICC,肝细胞癌(HCC),合并肝细胞胆管癌(CHC),良性病变,如良性肝血管瘤,局灶性结节增生,局灶性炎症和脂肪变性,血管畸形,和脂肪的节省,显示PSMA摄取升高。此外,PSMA-PET在检测ICC和HCC方面优于FDG-PET,这表明PSMA-PET可用作替代分期,并可用于确定PSMA靶向治疗的患者。
    Radionuclide probes-targeted prostate-specific membrane antigen (PSMA) is used in diagnosis and treatment of prostate cancer (PCa). Recent studies have shown that PSMA is expressed in the tumor neovascular endothelium, such as in malignant liver tumors. We report a case of PCa with incidental intrahepatic cholangiocarcinoma (ICC) detection using 18F-PSMA-1007 and 18F-fluorodeoxyglucose (FDG) positron emission topography (PET)/MRI.18F-PSMA-1007 PET/MRI of our patient with PCa showed that one liver lesion had high PSMA uptake. 18F-FDG PET/MRI revealed minimal FDG uptake in the liver lesion. Histopathological examination revealed that the liver lesion was moderately to poorly differentiated cholangiocarcinoma. Our studies, along with others, demonstrated that malignant liver tumors, such as ICC, hepatocellular carcinoma (HCC), and combined hepatocellular-cholangiocarcinoma (CHC), and benign lesions, such as benign liver hemangioma, focal nodular hyperplasia, focal inflammation and steatosis, vascular malformation, and fatty sparing, exhibited elevated PSMA uptake. Moreover, PSMA-PET was superior to FDG-PET in detecting ICC and HCC, indicating that PSMA-PET may be used as alternative staging and to identify patients for PSMA-targeted therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    人类免疫缺陷病毒的流行在全球范围内呈上升趋势。药物相关的尿路结石通常是由用于治疗HIV阳性患者的药物引起的。我们介绍了一例HIV阳性的39岁男性,患有输尿管支架结壳和肾结石。使用一次性输尿管软镜进行输尿管碎石术。术后进展良好。一次性输尿管软镜可有效治疗HIV合并输尿管支架结壳。
    Human immunodeficiency virus prevalence was increasing worldwide. Medication-associated urinary calculi are very commonly caused by medications used to treat HIV-positive patients. We present a case of an HIV-positive 39-year-old male with ureteral stent encrustation and kidney stone. Ureterolithotripsy using a disposable flexible ureteroscope is performed. The postoperative evolution was favorable. The disposable flexible ureteroscope is effective in the treatment of HIV combined with ureteral stent encrustation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在观察性研究中,血清25-羟基维生素D水平与勃起功能障碍(ED)相关。然而,它们之间是否存在因果关系仍然不确定。
    进行两个样本的孟德尔随机化(MR)分析,以调查血清25-羟基维生素D水平与ED风险之间的因果关系。
    来自496,949名欧洲血统的人的血清25-羟基维生素D水平的全基因组关联研究(GWAS)数据,包括6,896,093个单核苷酸多态性(SNP),被视为MR分析的暴露。其他GWAS数据涉及6,175例欧洲ED病例和217,630例对照中的9,310,196个SNP被用作结果数据。MR-Egger,逆方差加权(IVW)方法,加权中位数,简单模式,并采用加权模式来评估因果效应,其中IVW是主要的MR分析方法。通过异质性测试证实了MR分析结果的稳定性,水平多效性测试,和留一法。
    有103个SNP用作工具变量(p<5×10-8)。MR分析结果表明,血清25(OH)D浓度对ED风险没有因果关系(IVW;OR=0.9516,95%CI=0.7994至1.1328,p=0.5772)。统计模型中没有异质性和多效性。
    目前的MR研究不支持基因预测的血清25-羟基维生素D浓度与欧洲血统个体ED风险的因果关系。
    UNASSIGNED: Serum 25-hydroxyvitamin D level is associated with erectile dysfunction (ED) in observational studies. However, whether there is a causal association between them remains uncertain.
    UNASSIGNED: Conduct a two-sample Mendelian randomization (MR) analysis to investigate the causal effect between serum 25-hydroxyvitamin D level and ED risk.
    UNASSIGNED: Genome-wide association study (GWAS) data of serum 25-hydroxyvitamin D levels comprising 6,896,093 single nucleotide polymorphisms (SNP) from 496,949 people of European ancestry were regarded as exposure for the MR analysis. Additional GWAS data involving 9,310,196 SNPs of 6,175 European ED cases and 217,630 controls were used as outcome data. The MR-Egger, inverse variance weighted (IVW) method, weighted median, simple mode, and weighted mode were employed to evaluate causal effects, among which IVW was the primary MR analysis method. The stability of the MR analysis results was confirmed by a heterogeneity test, a horizontal pleiotropy test, and the leave-one-out method.
    UNASSIGNED: There were 103 SNPs utilized as instrumental variables (p < 5 × 10-8). The results of MR analysis showed no causal effects of serum 25(OH) D concentration on ED risks (IVW; OR = 0.9516, 95% CI = 0.7994 to 1.1328, p = 0.5772). There was no heterogeneity and pleiotropy in the statistical models.
    UNASSIGNED: The present MR study did not support a causal association for genetically predicted serum 25-hydroxyvitamin D concentration in the risk of ED in individuals of European descent.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    抗胸腺细胞球蛋白(ATG)是实体器官移植免疫抑制的基石。治疗是由过度免疫抑制引起的并发症(如感染和癌症)与由免疫抑制不足引起的排斥之间的微妙平衡。CD3+T淋巴细胞测量经常用于治疗监测。然而,这种分析成本很高,而且并不总是容易获得。这项研究的目的是根据我们移植中心的数据并结合文献综述,研究淋巴细胞总数是否可以代替CD3T淋巴细胞的测量。假设是总淋巴细胞计数可以作为CD3T淋巴细胞的诊断替代标记。
    进行了一项回顾性队列研究,包括接受肾脏和/或胰腺移植并接受ATG诱导治疗或排斥治疗的患者.纳入标准是在同一天同时测量总淋巴细胞计数和CD3T淋巴细胞测量值。此外,截至2023年10月18日,PubMed和Embase进行了关于实体器官移植的已发表研究,ATG,T淋巴细胞,淋巴细胞计数,和监测。在回顾性队列研究中,在2016年至2023年期间,共有91名患者移植,487个样本,包括在内。
    低于0.3×109/L的总淋巴细胞计数作为低于0.05×109/L的CD3+T淋巴细胞的替代标记具有很高的敏感性(86%),但总淋巴细胞计数高于0.3×109/L的特异性较低(52%),作为CD3+T淋巴细胞高于0.05×109/L的替代标记。对文献的回顾确定了七项在ATG监测中比较总淋巴细胞计数和CD3T淋巴细胞的研究。这些研究支持使用低总淋巴细胞计数作为CD3+T淋巴细胞的替代标记和省略ATG治疗的指标。然而,对于高总淋巴细胞计数作为继续治疗的指标尚无共识.
    结果支持当低于0.3x109/L时,总淋巴细胞计数可用于省略ATG治疗,而CD3T淋巴细胞分析应保留用于较高的总淋巴细胞计数,以避免ATG过度治疗。
    UNASSIGNED: Anti-Thymocyte Globulin (ATG) is a cornerstone in immune suppression for solid organ transplantation. The treatment is a delicate balance between complications arising from over-immunosuppression such as infections and cancer versus rejection stemming from under-immunosuppression. CD3+ T-lymphocyte measurements are frequently employed for treatment monitoring. However, this analysis is costly and not always accessible. The aim of this study was to investigate whether the total count of lymphocytes could replace CD3+ T-lymphocyte measurements based on data from our transplantation center combined with a review of the literature. The hypothesis was that the total lymphocyte count could serve as a diagnostic surrogate marker for CD3+ T-lymphocytes.
    UNASSIGNED: A retrospective cohort study was conducted, including patients who underwent kidney and/or a pancreas transplantation and received ATG as induction therapy or for rejection treatment. The inclusion criterium was that the total lymphocyte count and CD3+ T-lymphocyte measurements were measured simultaneously on the same day. Additionally, PubMed and Embase were searched up to 18/10/2023 for published studies on solid organ transplantation, ATG, T-lymphocytes, lymphocyte count, and monitoring. In the retrospective cohort study, a total of 91 patients transplanted between 2016 and 2023, with 487 samples, were included.
    UNASSIGNED: Total lymphocyte counts below 0.3 x 109/L had a high sensitivity (86%) as a surrogate marker of CD3+ T-lymphocytes below 0.05 x 109/L, but the specificity was low (52%) for total lymphocyte counts above 0.3 x 109/L as a surrogate marker for CD3+ T-lymphocytes above 0.05 x 109/L. A review of the literature identified seven studies comparing total lymphocyte counts and CD3+ T-lymphocytes in ATG monitoring. These studies supported the use of a low total lymphocyte count as a surrogate marker for CD3+ T-lymphocytes and an indicator to omit ATG treatment. However, there was no consensus regarding high total lymphocyte counts as an indicator for continued treatment.
    UNASSIGNED: Results supports that the total lymphocyte count can be used to omit ATG treatment when below 0.3 x 109/L whereas the CD3+ T-lymphocyte analysis should be reserved for higher total lymphocyte counts to avoid ATG overtreatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究旨在探讨影响严重甲状腺功能减退症患者急性肾损伤(AKI)发展的因素。
    这项回顾性观察性研究涉及原发性甲状腺功能减退症和促甲状腺激素(TSH)水平超过50mIU/L的患者,2015年1月至2021年4月。Logistic回归分析影响AKI发生发展的因素。
    总共100名患者,20(11名男性(M),9名女性(F))在AKI(病例)组中和80(23M,57F)对照组患者,包括在我们的研究中。病例组的中位年龄(56岁,四分位距(IQR)44.3-68.5)显着高于对照组(49岁,IQR32.3-60;p=0.027),病例组男女比例明显较高(p=0.001)。多因素logistic回归分析显示,60岁后诊断为甲状腺功能减退(比值比(OR)59.674,95%置信区间(CI)5.955-598.031;p=0.001),游离三碘甲状腺原氨酸(FT3)<1.3pg/mL(OR17.151,95%CI2.491-118.089;p=0.004)和肌酸激酶(CK)>1000U/L(OR1.522,95%CI1.602-82.848;p=0.015)是重度甲状腺功能减退症患者发生AKI的预测因子.
    我们建议密切随访和监测由严重甲状腺功能减退引起的AKI患者,如果患者在60岁以上被诊断,CK>1000U/L或FT3<1.3pg/mL。
    UNASSIGNED: This study aims to investigate the factors affecting development of acute kidney injury (AKI) in patients with severe hypothyroidism.
    UNASSIGNED: This retrospective observational study involved patients with primary hypothyroidism and thyroid stimulating hormone (TSH) levels of more than 50 mIU/L at their review in the endocrinology outpatient clinic, between January 2015 and April 2021. Factors affecting the development of AKI were examined by logistic regression analysis.
    UNASSIGNED: A total of 100 patients, 20 (11 male (M), 9 female (F)) in the AKI (case) group and 80 (23 M, 57 F) patients in control group, were included in our study. The median age of the case group (56 years, interquartile range (IQR) 44.3-68.5) was significantly higher than the control group (49 years, IQR 32.3-60; p = 0.027), and the ratio of males to females was significantly higher in the case group (p = 0.001). Multivariate logistic regression analyses showed that hypothyroidism diagnosed after the age of 60 years (odds ratio (OR) 59.674, 95% confidence intervals (CI) 5.955-598.031; p = 0.001), free triiodothyronine (FT3) < 1.3 pg/mL (OR 17.151, 95% CI 2.491-118.089; p = 0.004) and creatine kinase (CK) > 1000 U/L (OR 1.522, 95% CI 1.602-82.848; p = 0.015) were predictors for the development of AKI in patients with severe hypothyroidism.
    UNASSIGNED: We recommend close follow-up and monitoring of patients with AKI caused by severe hypothyroidism if patients who are diagnosed at age > 60 years, CK > 1000 U/L or FT3 < 1.3 pg/mL.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的68镓前列腺特异性膜抗原(68Ga-PSMA)成像对分期有价值,因为准确的诊断,前列腺癌患者的转移性或非转移性,是决定治疗方法和预后评估所必需的。这项研究的目的主要是区分68Ga-PSMA正电子发射断层扫描(PET)/CT成像期间检测到的良性和转移性肾上腺病变,为了评估预测其发展的因素的存在,然后确定转移性肾上腺病变患者的预期寿命。材料与方法我们对2016年6月至2021年2月产生的“肾上腺”PET/CT记录进行了数据库搜索,这些记录是针对68例前列腺癌患者进行Ga-PSMA检查的患者的报告。结果23例患者(良性10例,转移性13例)纳入本研究。总前列腺特异性抗原,肾上腺大小,肾上腺密度,和最大标准化摄取(SUVmax)值在组间显著不同(p<0.05)。关于接收机工作特性曲线分析,SUVmax临界值>6.8提供100%的敏感性和特异性.然而,以29毫米为肾上腺尺寸截止值,以21.2为Hounsfield单位,敏感性和特异性分别为56.2和92.3%,93.8%和92.3%,分别。比较了良性和转移组的生存率,发现了统计学上的显着差异(p=0.006)。盆腔淋巴结的存在对两组之间的监测产生了统计学上的负面影响。结论前列腺癌患者肾上腺等非典型转移的存在并不明显。由于这种对患者管理的影响程度,通过68Ga-PSMA成像进行准确分期应是前列腺癌治疗不可或缺的一部分.
    Objectives  Gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) imaging is valuable for staging because an accurate diagnosis, metastatic or nonmetastatic for prostate cancer patients, is required for deciding to treatment approaches and prognostic assessment. The aim of this study was primarily to distinguish between benign and metastatic adrenal gland lesions detected during 68 Ga-PSMA positron emission tomography (PET)/CT imaging, to evaluate the presence of factors predicting its development, and then to determine the life expectancy of patients with metastatic adrenal lesions. Materials and Methods  We performed a database search for PET/CT records generated from June 2016 to February 2021 for \"adrenal gland\" in report for patients who underwent 68 Ga-PSMA examination with prostate cancer patients. Results  Twenty-three patients (10 benign and 13 metastatic) were included in this study. The total prostate-specific antigen, adrenal gland size, adrenal gland density, and maximum standardized uptake (SUVmax) values are significantly different between groups ( p  < 0.05). On receiver operating characteristic curve analysis, the SUVmax cutoff value > 6.8 provided both sensitivity and specificity of 100%. However, with 29 mm as the adrenal gland size cutoff and 21.2 as Hounsfield unit, the sensitivity and specificity were 56.2 and 92.3%, and 93.8 and 92.3%, respectively. The survival of the benign and metastatic groups was compared and a statistically significant difference was found ( p  = 0.006). The presence of pelvic lymph nodes was statistically negatively affected the surveillance between the groups. Conclusion  The presence of atypical metastases such as adrenal gland is not insignificant in prostate cancer patients. Because of this degree of impact on patient management, accurate staging by imaging with 68 Ga-PSMA should be an integral part of prostate cancer management.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景技术多参数磁共振成像(mpMRI)被广泛用于前列腺癌的评估,并且已知具有更好的准确性。镓-68前列腺特异性膜抗原(Ga-68PSMA)是在前列腺癌细胞中显示高度定位的放射性示踪剂。目的本研究的目的是评估Ga-68PSMA正电子发射断层扫描/计算机断层扫描(PET/CT)的敏感性和实用性,与mpMRI相比,作为一种非侵入性成像技术用于前列腺癌的初始诊断和局部分期使用直肠超声(TRUS)引导活检作为金标准。材料与方法这项前瞻性观察性研究于2017年8月至2020年4月进行,评估了60例(n=60)经活检证实为前列腺癌的男性。他们在14天内接受了mpMRI和Ga-68PSMAPET/CT扫描,TRUS活检是金标准。疾病的T分期,骨盆内淋巴结的N分期,使用PSPP1.0.1版统计软件比较了骨盆骨病变的M分期(在mpMRI的成像范围内)。结果60例平均年龄为69.9±9.35岁的男性均表现为Ga-68PSMA狂热病,而通过mpMRI检测到55。Ga-68PSMAPET/CT检测前列腺病变的灵敏度(95%置信区间)为99.08%,mpMRI为84.40%。与mpMRI(12/60)相比,Ga-68PSMAPET/CT检测到更多的区域淋巴结受累患者(19/60)。Ga-68PSMAPET/CT显示9例患者的PSMA狂热骨盆骨骼病变,而mpMRI检测到6例患者的盆腔病变。此外,另外4例患者在Ga-68PSMAPET/CT上显示肾盂外骨骼病变。结论Ga-68PSMAPET/CT对原发性前列腺肿瘤的检出具有较高的敏感性,与MPMRI相比。两种方式在检测精囊受累方面都有很好的相关性。Ga-68PSMAPET/CT在检测淋巴结和骨骼转移方面优于mpMRI。因此,Ga-68PSMAPET/CT应被视为前列腺癌的一线诊断方式。总结声明:Ga-68PSMAPET/CT在前列腺癌的评估中显示出比mpMRI更好的诊断性能。
    Background  Multiparametric magnetic resonance imaging (mpMRI) is widely used for the evaluation of prostate cancer and is known to have better accuracy. Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) is a radiotracer that shows high localization in prostate cancer cells. Purpose  The purpose of this study was to assess the sensitivity and utility of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in comparison with mpMRI as a noninvasive imaging technique for the initial diagnosis and locoregional staging of prostate cancer using transrectal ultrasound (TRUS)-guided biopsy as gold standard. Materials and Methods  This prospective observational study conducted from August 2017 to April 2020 evaluated 60 men ( n  = 60) with biopsy-proven prostate carcinoma. They underwent mpMRI and Ga-68 PSMA PET/CT scans within 14 days with TRUS biopsy being gold standard. T staging of disease, N staging of lymph nodes within the pelvis, and M staging of lesions in pelvic bones (within the imaging field of mpMRI) were compared using PSPP version 1.0.1 statistical software. Results  All 60 men with a mean age of 69.9 ± 9.35 years showed Ga-68 PSMA avid disease, whereas 55 were detected by mpMRI. The sensitivity in detection of prostate lesions (with 95% confidence interval) was 99.08% for Ga-68 PSMA PET/CT and 84.40% for mpMRI. Ga-68 PSMA PET/CT detected greater number of patients with regional lymph nodal involvement (19/60) as compared with mpMRI (12/60). Ga-68 PSMA PET/CT showed PSMA avid pelvic skeletal lesions in nine patients, whereas mpMRI detected pelvic lesions in six patients. In addition, four other patients showed extrapelvic skeletal lesions on Ga-68 PSMA PET/CT. Conclusion  Ga-68 PSMA PET/CT has superior sensitivity in detection of primary prostate tumor, as compared with mpMRI. Both modalities correlate well in detection of seminal vesicle involvement. Ga-68 PSMA PET/CT outperformed mpMRI in detection of lymph nodal and skeletal metastases. Hence, Ga-68 PSMA PET/CT should be considered as first-line diagnostic modality for carcinoma prostate. Summary Statement : Ga-68 PSMA PET/CT shows superior diagnostic performance than mpMRI in the evaluation of prostate cancer.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在这项研究中,分析了10年的采购质量监测数据,以确定与采购相关损伤相关的潜在风险因素及其与移植物长期存活的关系。所有死去的肾脏,肝脏,和2012年至2022年的胰腺供体及其在荷兰的相应受体被回顾性纳入.分析采购相关伤害发生率及潜在危险因素。在所有获得的腹部器官中,23%的人出现采购相关伤害,丢弃率为4.0%。在肾脏和肝脏中,23%的移植物有采购相关的伤害,2.5%和4%的与采购相关的伤害器官被丢弃,分别。在胰腺采购中,这是27%,丢弃率为24%。男性供体性别和供体BMI>25是所有三个腹部器官采购相关损伤的显著危险因素,而异常血管形成仅对肾脏和肝脏有意义。在多变量Cox回归分析中,采购相关损伤不是移植物衰竭的显著预测因子(肾脏;HR0.99,95%CI0.75-1.33,p=0.99,肝脏;HR0.92,95%CI0.66-1.28,p=0.61,胰腺:HR1.16;95%CI0.16-8.68,p=0.88).这项研究的结果表明,移植外科医生在确定与采购相关的伤害的可接受性和可修复性方面表现出良好的决策能力。
    In this study, 10 years of procurement quality monitoring data were analyzed to identify potential risk factors associated with procurement-related injury and their association with long-term graft survival. All deceased kidney, liver, and pancreas donors from 2012 to 2022 and their corresponding recipients in the Netherlands were retrospectively included. The incidence of procurement-related injuries and potential risk factors were analyzed. Of all abdominal organs procured, 23% exhibited procurement-related injuries, with a discard rate of 4.0%. In kidneys and livers, 23% of the grafts had procurement-related injury, with 2.5% and 4% of organs with procurement-related injury being discarded, respectively. In pancreas procurement, this was 27%, with a discard rate of 24%. Male donor gender and donor BMI >25 were significant risk factors for procurement-related injury in all three abdominal organs, whereas aberrant vascularization was significant only for the kidney and liver. In the multivariable Cox regression analyses, procurement-related injury was not a significant predictor for graft failure (kidney; HR 0.99, 95% CI 0.75-1.33, p = 0.99, liver; HR 0.92, 95% CI 0.66-1.28, p = 0.61, pancreas: HR 1.16; 95% CI 0.16-8.68, p = 0.88). The findings of this study suggest that transplant surgeons exhibited good decision-making skills in determining the acceptability and repairability of procurement-related injuries.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号